Real-world occurrence, therapy, and outcome of patients with class 2 or 3 BRAF compared with class 1 BRAF-mutated cancers

Real-world occurrence, therapy, and outcome of patients with class 2 or 3 BRAF compared with class 1 BRAF-mutated cancers

Background: BRAF V600 mutations are the epitome of targeted therapy. However, not much is known about non-V600 mutations. Using the new data infrastructure of the Swiss Personalized Oncology project of the Swiss Personalized Health Network (SPHN), we evaluated the fate of patients with cancer with n...

Full description

Saved in:
Bibliographic Details
Main Authors: S. Pradervand, N. Freundler, B. Gosztonyi, L. Roncoroni, R. Achermann, T. Schwenk, G. de Fraipont, J. Garessus, S. Haefliger, A.B. Leichtle, M.K. Kiessling, T. Mueller-Focke, F.S. Krebs, V. Zoete, P. Tsantoulis, O. Michielin, C. Britschgi, A. Wicki
Format: Article
Language:English
Published: Elsevier 2024-12-01
Series:ESMO Real World Data and Digital Oncology
Subjects:
BRAF mutations
precision oncology
personalized treatment
Swiss Personalized Health Network (SPHN)
Online Access:http://www.sciencedirect.com/science/article/pii/S2949820124000535
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

http://www.sciencedirect.com/science/article/pii/S2949820124000535

Similar Items